These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17433706)

  • 1. Energy transfer to analyse membrane-integrated mitoxantrone in BCRP-overexpressed cells.
    Breuzard G; El-Khoury V; Millot C; Manfait M; Millot JM
    J Photochem Photobiol B; 2007 May; 87(2):113-23. PubMed ID: 17433706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in adsorption and permeability of mitoxantrone on plasma membrane of BCRP/MXR resistant cells.
    Breuzard G; Piot O; Angiboust JF; Manfait M; Candeil L; Del Rio M; Millot JM
    Biochem Biophys Res Commun; 2005 Apr; 329(1):64-70. PubMed ID: 15721274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
    Volk EL; Schneider E
    Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of cyclosporin a with breast cancer resistance protein.
    Xia CQ; Liu N; Miwa GT; Gan LS
    Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.
    Volk EL; Rohde K; Rhee M; McGuire JJ; Doyle LA; Ross DD; Schneider E
    Cancer Res; 2000 Jul; 60(13):3514-21. PubMed ID: 10910063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
    González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
    Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
    Rhee MS; Schneider E
    Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface-enhanced Raman scattering reveals adsorption of mitoxantrone on plasma membrane of living cells.
    Breuzard G; Angiboust JF; Jeannesson P; Manfait M; Millot JM
    Biochem Biophys Res Commun; 2004 Jul; 320(2):615-21. PubMed ID: 15219873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.
    Rabindran SK; Ross DD; Doyle LA; Yang W; Greenberger LM
    Cancer Res; 2000 Jan; 60(1):47-50. PubMed ID: 10646850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.
    Solazzo M; Fantappiè O; D'Amico M; Sassoli C; Tani A; Cipriani G; Bogani C; Formigli L; Mazzanti R
    Cancer Res; 2009 Sep; 69(18):7235-42. PubMed ID: 19706772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
    Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].
    Yuan JH; He ZM; Yu YH; Chen ZC
    Ai Zheng; 2004 Oct; 23(10):1127-33. PubMed ID: 15473921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
    Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH
    Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells.
    Jendželovská Z; Jendželovský R; Hiľovská L; Kovaľ J; Mikeš J; Fedoročko P
    Toxicol In Vitro; 2014 Oct; 28(7):1259-73. PubMed ID: 24994473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
    Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
    Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
    Volk EL; Farley KM; Wu Y; Li F; Robey RW; Schneider E
    Cancer Res; 2002 Sep; 62(17):5035-40. PubMed ID: 12208758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.